Genmab A/S (GMAB) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $37.00, -2.17% vs the prior close of $37.82.
- Volume 2.68M shares, 0.8x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
GMAB dips 2.2% to $37.00. Closed at $37.00, -2.17% vs the prior close of $37.82. Day range $36.74–$38.20, opened at $38.15.
GMAB daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — GMAB dips 2.2% to $37.00
- Closed at $37.00, -2.17% vs the prior close of $37.82. Day range $36.74–$38.20, opened at $38.15.
- Volume was 2.68M shares, 0.8x its 50-day average of 3.20M.
- Price is +7.8% vs its 50-day average ($34.31) and +23.9% vs its 200-day average ($29.86).
- 52-week range $23.62–$40.17; today's close sits at 81% of that range, 7.9% below the 52-week high.
Oct 15, 2026 — GMAB rises 2.5% to $37.82
- Closed at $37.82, +2.52% vs the prior close of $36.89. Day range $37.04–$38.33, opened at $37.20.
- Volume was 4.08M shares, 1.3x its 50-day average of 3.14M.
- Price is +10.7% vs its 50-day average ($34.17) and +26.8% vs its 200-day average ($29.83).
- 52-week range $23.62–$40.17; today's close sits at 86% of that range, 5.9% below the 52-week high.
Oct 14, 2026 — GMAB rises 0.9% to $36.89
- Closed at $36.89, +0.88% vs the prior close of $36.57. Day range $36.12–$37.24, opened at $36.38.
- Volume was 2.69M shares, 0.9x its 50-day average of 3.12M.
- Price is +8.5% vs its 50-day average ($34.00) and +23.8% vs its 200-day average ($29.81).
- 52-week range $23.62–$40.17; today's close sits at 80% of that range, 8.2% below the 52-week high.
Oct 13, 2026 — GMAB dips 2.1% to $36.57
- Closed at $36.57, -2.14% vs the prior close of $37.37. Day range $36.34–$37.35, opened at $37.23.
- Volume was 3.74M shares, 1.2x its 50-day average of 3.08M.
- Price is +8.1% vs its 50-day average ($33.84) and +22.8% vs its 200-day average ($29.79).
- 52-week range $23.62–$40.17; today's close sits at 78% of that range, 9.0% below the 52-week high.
- SEC filings that day: 6-K.
Oct 12, 2026 — GMAB rises 0.8% to $37.37
- Closed at $37.37, +0.81% vs the prior close of $37.07. Day range $36.94–$37.71, opened at $37.18.
- Volume was 3.13M shares, 1.0x its 50-day average of 3.06M.
- Price is +10.9% vs its 50-day average ($33.68) and +25.5% vs its 200-day average ($29.77).
- 52-week range $23.62–$40.17; today's close sits at 83% of that range, 7.0% below the 52-week high.
Oct 9, 2026 — GMAB rises 2.8% to $37.07
- Closed at $37.07, +2.83% vs the prior close of $36.05. Day range $36.33–$37.15, opened at $36.55.
- Volume was 2.33M shares, 0.8x its 50-day average of 3.04M.
- Price is +10.6% vs its 50-day average ($33.51) and +24.6% vs its 200-day average ($29.76).
- 52-week range $23.62–$40.17; today's close sits at 81% of that range, 7.7% below the 52-week high.
Oct 8, 2026 — GMAB dips 1.6% to $36.05, 3 down days in a row
- Closed at $36.05, -1.64% vs the prior close of $36.65. Day range $35.09–$36.28, opened at $36.17.
- Volume was 4.30M shares, 1.4x its 50-day average of 2.98M.
- Price is +8.1% vs its 50-day average ($33.35) and +21.2% vs its 200-day average ($29.74).
- 52-week range $23.62–$40.17; today's close sits at 75% of that range, 10.3% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — GMAB slides 3.0% to $36.65
- Closed at $36.65, -3.04% vs the prior close of $37.80. Day range $36.27–$37.87, opened at $37.28.
- Volume was 4.25M shares, 1.4x its 50-day average of 2.94M.
- Price is +10.4% vs its 50-day average ($33.20) and +23.3% vs its 200-day average ($29.72).
- 52-week range $23.62–$40.17; today's close sits at 79% of that range, 8.8% below the 52-week high.
- SEC filings that day: 6-K.
Oct 6, 2026 — GMAB dips 1.8% to $37.80 on 2.3x normal volume
- Closed at $37.80, -1.77% vs the prior close of $38.48. Day range $37.07–$39.15, opened at $39.11.
- Volume was 6.60M shares, 2.3x its 50-day average of 2.84M — unusually heavy trading.
- Price is +14.4% vs its 50-day average ($33.04) and +27.3% vs its 200-day average ($29.69).
- 52-week range $23.62–$40.17; today's close sits at 86% of that range, 5.9% below the 52-week high.
Oct 5, 2026 — GMAB jumps 10.7% to $38.48, a 52-week high on 4.7x normal volume
- Closed at $38.48, +10.73% vs the prior close of $34.75. Day range $35.02–$40.17, opened at $35.09.
- Volume was 12.40M shares, 4.7x its 50-day average of 2.62M — unusually heavy trading.
- Price is +17.1% vs its 50-day average ($32.86) and +29.7% vs its 200-day average ($29.66).
- 52-week range $23.62–$40.17; today's close sits at 90% of that range, 4.2% below the 52-week high.
- SEC filings that day: 6-K.
Oct 2, 2026 — GMAB rises 0.6% to $34.75 on 2.1x normal volume
- Closed at $34.75, +0.58% vs the prior close of $34.55. Day range $33.72–$35.02, opened at $34.39.
- Volume was 5.44M shares, 2.1x its 50-day average of 2.54M — unusually heavy trading.
- Price is +6.4% vs its 50-day average ($32.67) and +17.3% vs its 200-day average ($29.63).
- 52-week range $23.62–$35.90; today's close sits at 91% of that range, 3.2% below the 52-week high.
- SEC filings that day: 6-K.
GMAB latest news & SEC filings
Every SEC filing by or about GMAB in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Oct 7, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Oct 5, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Oct 5, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Oct 2, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 29, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 24, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 9, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 9, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 8, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 11, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 6, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Jul 15, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Things to know before you trade GMAB
- How much it moves: over the last 20 sessions the average daily move was 1.90% (largest 10.7%).
- Liquidity: about 4.11M shares (≈$152.21M) trade per day on average.
- 52-week position: $37.00 vs a range of $23.62–$40.17 (81% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 6-K Oct 13, 2026; 6-K Oct 7, 2026; 6-K Oct 5, 2026.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
GMAB market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 38.15 | 38.20 | 36.74 | 37.00 | 2.68M |
| Oct 15, 2026 | 37.20 | 38.33 | 37.04 | 37.82 | 4.08M |
| Oct 14, 2026 | 36.38 | 37.24 | 36.12 | 36.89 | 2.69M |
| Oct 13, 2026 | 37.23 | 37.35 | 36.34 | 36.57 | 3.74M |
| Oct 12, 2026 | 37.18 | 37.71 | 36.94 | 37.37 | 3.13M |
| Oct 9, 2026 | 36.55 | 37.15 | 36.33 | 37.07 | 2.33M |
| Oct 8, 2026 | 36.17 | 36.28 | 35.09 | 36.05 | 4.30M |
| Oct 7, 2026 | 37.28 | 37.87 | 36.27 | 36.65 | 4.25M |
| Oct 6, 2026 | 39.11 | 39.15 | 37.07 | 37.80 | 6.60M |
| Oct 5, 2026 | 35.09 | 40.17 | 35.02 | 38.48 | 12.40M |
| Oct 2, 2026 | 34.39 | 35.02 | 33.72 | 34.75 | 5.44M |
| Oct 1, 2026 | 35.25 | 35.80 | 34.51 | 34.55 | 6.38M |
| Sep 30, 2026 | 35.72 | 35.90 | 35.37 | 35.67 | 5.15M |
| Sep 29, 2026 | 34.94 | 35.64 | 34.89 | 35.57 | 3.83M |
| Sep 28, 2026 | 34.76 | 35.70 | 34.63 | 35.36 | 2.79M |
| Sep 25, 2026 | 34.95 | 35.47 | 34.70 | 35.32 | 3.58M |
| Sep 24, 2026 | 34.69 | 35.03 | 34.36 | 34.83 | 2.51M |
| Sep 23, 2026 | 35.39 | 35.66 | 34.60 | 34.75 | 2.51M |
| Sep 22, 2026 | 34.46 | 35.29 | 34.37 | 35.22 | 2.30M |
| Sep 21, 2026 | 34.70 | 34.87 | 34.36 | 34.69 | 1.58M |
About Genmab A/S
Genmab A/S (GMAB) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in 1253 COPENHAGEN K, Denmark. Fiscal year ends —. SEC CIK 1434265.
GMAB board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| No Form 3/4/5 filings by this group in the last 12 months. | ||
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| No Form 3/4/5 filings by this group in the last 12 months. | ||
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
GMAB financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $—, total liabilities $—, cash $—.
GMAB earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| No 8-K earnings releases in recent filings. | ||
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on GMAB
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.